Dihexa Dosage: Nootropic Protocol and Safety

Let me be direct from the start: Dihexa is the peptide I am most cautious about, and I believe that caution is warranted by the evidence profile. Dihexa is extraordinarily potent as a synaptogenic agent in cell culture — the preclinical data suggesting it is seven orders of magnitude more potent than BDNF was remarkable. But potency without safety data is not a virtue. It is a risk.

This dosing guide exists because patients will seek this information regardless, and I would rather provide an honest, evidence-graded assessment than have people rely on forum posts. But my position is clear: the risk-benefit profile of Dihexa is not resolved, and its use should be approached with far more caution than most peptide therapy providers currently exercise.

At a Glance

Protocol Table: Dose, Route, Timing and Basis

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

One row per use case. Every row is Anecdotal: dihexa has never been given to humans in a published study, and the FDA has identified no human exposure data. The two compilations below agree on the oral range, which tells you what people take, not what is safe.

No cycle length rests on any human data. The long cycles (90 days) extend exposure to the c-Met pathway discussed below.

What Dihexa Is and What It Does

Dihexa came out of a research programme at Washington State University that tried to turn angiotensin IV, a small peptide with memory effects in rodents, into a usable drug. The team modified the molecule to resist breakdown and cross the blood-brain barrier. In their 2013 paper, the resulting compound restored learning in rats given scopolamine and in aged rats, and it increased synapse formation in cultured neurons (McCoy et al., 2013).

The proposed mechanism is hepatocyte growth factor (HGF) and its receptor, c-Met. In the follow-up paper, Dihexa’s effect in rats was blocked when an HGF antagonist was given into the brain, which the authors read as proof that the effect ran through HGF/c-Met (Benoist et al., 2014, since retracted). HGF/c-Met does support neuron survival and synapse growth. It also drives cell growth, movement and new blood vessels in many other tissues (Organ & Tsao, 2011).

Online sources often add that Dihexa is millions of times more potent than BDNF. That comparison comes from cell-culture work by the developing group. It says nothing about effects in a living human brain.

Dihexa Dosage: What Exists and What Does Not

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

I want to be transparent: there are no human dose-finding studies for Dihexa. Every dosing protocol in circulation is derived from one of two sources:

1. Animal study extrapolation. The original McCoy et al. research used Dihexa at picomolar concentrations in cultured neurons and, in rats, at 0.05-0.5 mg/kg by intraperitoneal injection and 2 mg/kg orally. Allometric scaling to human-equivalent doses produces estimates, but these are not validated.

2. Community-derived protocols. The 5-20 mg oral and 2-5 mg subcutaneous doses commonly cited online emerged from user experimentation, not clinical research. These numbers should be treated as anecdotal, not evidence-based.

The Animal Data That Drives Current Dosing

The foundational study (McCoy et al., 2013 — now under a notice of concern, which I will address) used Dihexa in rats with scopolamine-induced cognitive impairment and in aged rats:

• Dihexa was administered intracerebroventricularly (directly into the brain ventricles), by intraperitoneal injection (0.05-0.5 mg/kg; 0.5 mg/kg worked, 0.05 mg/kg did not) and orally by gavage (2 mg/kg daily)
• Oral activity was demonstrated, which is unusual for peptide-like compounds and is one of Dihexa’s distinguishing features
• Learning in the Morris water maze was restored in scopolamine-treated young rats and improved in 24-month-old rats; the effective oral dose of 2 mg/kg translates to roughly 20 mg in a 70 kg adult using standard body-surface scaling

The oral bioavailability claim is significant because most peptides are degraded in the GI tract. Dihexa is technically a modified dipeptide (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) with structural features that confer protease resistance. This makes oral dosing potentially viable, but human oral bioavailability has never been directly measured.

Current Community Protocols

Sources for every row are in the protocol table at the top of this guide.

My position: I do not recommend these protocols as standard clinical practice. I present them because patients will encounter them and deserve honest contextualization. The doses above are not validated by human research.

The Evidence: What We Actually Have

Preclinical

All published efficacy data for Dihexa come from rodents and cell cultures, and from one research group. That group’s record has since been formally questioned:

• 2021: the Journal of Pharmacology and Experimental Therapeutics issued notices of concern for both the 2013 and the 2014 papers (notice for McCoy 2013; notice for Benoist 2014).
• 2025: the 2014 paper, the one that established the HGF/c-Met mechanism, was retracted (retraction notice).

A retraction means the journal no longer stands behind the data. HGF/c-Met biology itself is well established by other groups. What is now unsupported is the specific evidence that Dihexa works through it at the potency claimed.

Human

This is directly relevant to Dihexa dosing discussions because fosgonimeton was designed as the clinically developed version of the same HGF-system idea. Fosgonimeton is a different molecule, so its failure does not prove Dihexa would fail. It does raise the question of whether HGF/c-Met activation is sufficient to produce meaningful cognitive improvement in humans — regardless of how impressive the preclinical data appeared.

What Remains Valid

Despite the retraction and clinical failure, certain aspects of the science are independently supported:

• HGF/c-Met signaling does promote synaptogenesis. This is established in the broader neuroscience literature, independent of the developing group’s papers.
• c-Met activation can enhance neuroplasticity. Multiple research groups have confirmed this pathway’s role in learning and memory.

What is not established: whether Dihexa at achievable doses in humans actually produces meaningful cognitive enhancement, whether it acts through c-Met at all now that the mechanism paper is retracted, and whether the potency claims are accurate.

What I See When Coaching Patients

I will be honest: my experience with Dihexa is limited, because the evidence profile makes me reluctant to support its use. People who have already used Dihexa report variable results:

• Some describe noticeable improvements in verbal fluency and memory recall within the first week of use
• Others report no perceptible effect
• A subset report vivid dreams and mild headaches
• None of them has reported serious adverse effects at the commonly used doses

These observations are anecdotal and subject to placebo effects. The variability in reported experience is not surprising given the absence of dose-optimization studies.

The c-Met Safety Question

This is the section that matters most, and the reason I approach Dihexa differently from other nootropic peptides.

The HGF/c-Met pathway is not exclusively a neuroplasticity pathway. It is a growth factor signaling axis involved in:

• Embryonic development. Cell migration, proliferation, and differentiation.
• Wound healing. Tissue repair and regeneration.
• Cancer. c-Met is a proto-oncogene. Aberrant HGF/c-Met signaling promotes tumor growth, angiogenesis, invasion, and metastasis in multiple cancer types including lung, liver, gastric, and breast cancer (Organ & Tsao, 2011).

The pharmaceutical industry has spent billions developing c-Met inhibitors as cancer drugs. Crizotinib, cabozantinib, and capmatinib are all c-Met inhibitors used in oncology. The fact that the oncology field is trying to suppress the very pathway that Dihexa activates should give anyone pause.

For a detailed analysis of this concern, see Dihexa Safety: The c-Met Cancer Risk Question.

What is known:

• No study has shown that Dihexa causes cancer in animals or humans
• The published animal studies did not report increased tumor incidence, but no long-term animal carcinogenicity study has been published
• The theoretical risk is mechanistically plausible but not empirically demonstrated

What is not known:

• Long-term effects of intermittent c-Met activation in humans
• Whether Dihexa at commonly used doses produces sufficient c-Met activation to influence tumor biology
• Whether patients with subclinical malignancies are at increased risk

Other Risks

Unknown pharmacology in humans. Absorption, half-life, metabolites, interactions and effects on the heart, liver and kidneys are all unmeasured.

Product quality. Dihexa is sold as a “research chemical”. These products are not made to pharmaceutical standards, and their identity, purity, dose and sterility are not independently verified. When researchers test-bought another peptide drug (semaglutide) from unregulated online sellers, the vials held far less active drug than labelled and all contained endotoxin (Ashraf et al., 2024). There is no reason to assume research-grade Dihexa is cleaner.

Injection-related harm. Anything injected from a non-sterile source carries a risk of local infection, abscess and, rarely, bloodstream infection. The FDA also flags immunogenicity and impurity risks for peptide products in general.

If You Proceed: Practical Considerations

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

For patients who, after understanding the evidence limitations and safety concerns, choose to use Dihexa under medical supervision, the following considerations apply:

Dosing Approach

All figures are anecdotal (community compilations, sourced in the protocol table above); none has been tested in humans.

Who Should NOT Use Dihexa

• Anyone with active cancer or history of cancer (c-Met concern)
• Anyone with a strong family history of cancer (particularly lung, liver, gastric, breast)
• Anyone with unresolved elevated tumor markers
• Pregnant or lactating women
• Anyone under 25 (brain development is still occurring)
• Anyone not under active physician supervision
• Competitive athletes (prohibited under WADA S0 and S2.3)

Monitoring

If Dihexa is used, I recommend:

1. Baseline cancer screening appropriate for age and risk factors
2. Baseline cognitive testing (standardized assessment, not self-report) to establish measurable endpoints
3. Liver function tests at baseline and after the first course
4. Follow-up cognitive testing at the end of each course
5. Ongoing cancer screening on an accelerated schedule for patients who use Dihexa repeatedly

Timing and Administration

• Morning dosing is preferred due to the activating cognitive effects
• Oral dosing on an empty stomach may improve absorption (theoretical — not human-tested)
• Subcutaneous injection provides more reliable delivery but bypasses the question of oral bioavailability

Alternatives with Better Evidence

For patients seeking nootropic peptide therapy, I want to present the alternatives that have stronger evidence-to-risk ratios:

The honest assessment: Semax and Selank provide meaningful nootropic and cognitive effects with established safety profiles and clinical trial support, although neither is approved outside Russia. Cerebrolysin has the strongest Western clinical evidence for neurological conditions. Dihexa has the most impressive potency claims but the weakest evidence foundation and the most concerning safety profile.

Regulatory Status

• United States (FDA): not an approved drug. On the FDA page Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026), dihexa acetate is listed among substances formerly in category 2 whose compounding nominations were withdrawn. The FDA states there that it “has not identified any human exposure data” for dihexa by any route, and that it lacks the information to know whether it would cause harm. Dihexa is not on the 503A bulks list and is not in category 1 (“under evaluation”) of FDA’s May 2026 list, so there is no recognised route for US pharmacies to compound it from bulk.
• EU and Germany: not authorised by the European Medicines Agency or Germany’s BfArM. Selling a vial as “research use only” avoids drug approval; it says nothing about whether the contents are safe or tested in people.
• Sport (WADA 2026 Prohibited List): prohibited at all times. As an unapproved substance it falls under S0, and HGF and other growth-factor modulators are named under S2.3.

When to Talk to a Physician

Most people who look up Dihexa are worried about memory, focus or mental stamina. Those complaints have many treatable causes: sleep apnoea, depression, thyroid disease, B12 deficiency, medication side effects, hearing loss, and early neurodegenerative disease that benefits from early diagnosis. A proper work-up looks for those first.

See a physician promptly if you notice memory changes that others comment on, getting lost in familiar places, new word-finding difficulty, or personality change. If you have already used Dihexa, tell your doctor what you took, from which source, for how long and by what route, and mention any new lumps, unexplained weight loss or other symptoms.

The Bottom Line

Dihexa dosing protocols exist in the community (5-20 mg oral, 2-5 mg subcutaneous, 4-8 week cycles), but they are not validated by human research. The key mechanism paper has been retracted, the original rat paper carries a notice of concern, the related HGF-pathway drug fosgonimeton failed in Alzheimer’s disease, and the mechanism of action involves a well-established pro-oncogenic pathway. I cannot recommend Dihexa as a standard nootropic intervention given the current evidence. For patients who choose to use it after informed discussion, cancer screening and physician supervision are the minimum appropriate precautions, and every extra week of a cycle is extra exposure to an untested compound. Safer nootropic peptide alternatives exist and should be considered first.

Back to Dihexa Overview | All Peptide Articles

Related Reading

• Dihexa: The Cognitive Peptide with Limited Data
• Dihexa Safety: The c-Met Cancer Risk Question
• Selank Dosage: Nasal Spray Protocol and Cycling